Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy.
Redox Biol. 2019 Feb;21:101070. doi: 10.1016/j.redox.2018.101070. Epub 2018 Dec 7.
Obesity and related pathologies such as diabetes and metabolic syndrome are associated with chronic inflammation and cancer. The serum level of xanthine oxidoreductase (XOR) is correlated to obesity-associated metabolic disorders. XOR can play a role in the pathogenesis of both metabolic syndrome and cancer through the inflammatory response and the oxidative stress elicited by the products of its activity. The reactive oxygen and nitrogen species and the uric acid derived from XOR concur to the development of hypertension, dyslipidemia and insulin resistance and participate in both cell transformation and proliferation, as well as in the progression and metastasis process. Despite the availability of different drugs to inhibit in vivo XOR activity, the complexity of XOR inhibition effects should be carefully considered before clinical application, save in the case of symptomatic hyperuricemia.
肥胖症及相关病理，如糖尿病和代谢综合征，与慢性炎症和癌症相关。黄嘌呤氧化还原酶（XOR）的血清水平与肥胖相关的代谢紊乱有关。XOR 可以通过其活性产物引起的炎症反应和氧化应激，在代谢综合征和癌症的发病机制中发挥作用。活性氧和氮物种以及来自 XOR 的尿酸共同导致高血压、血脂异常和胰岛素抵抗的发展，并参与细胞转化和增殖，以及进展和转移过程。尽管有不同的药物可抑制体内 XOR 活性，但在临床应用之前，应仔细考虑 XOR 抑制作用的复杂性，无症状性高尿酸血症除外。
